BLOOD CANCER TREATMENT:
CAR-T, TRANSPLANT & TARGETED THERAPY
China offers the world's most accessible CAR-T therapy at USD 35–75K. India provides world-class transplants from USD 20K. CancerFax navigates leukemia, lymphoma, and myeloma patients to the right specialist, right country, right treatment.
analyticsAt a Glance
- check_circleBlood cancers include leukaemia, lymphoma, myeloma, and myelodysplastic syndromes (MDS)
- check_circleTreatment options range from chemotherapy and targeted therapy to transplant and CAR-T cell therapy
- check_circleChina and India offer specialist blood cancer programmes at significantly lower cost
- check_circleCancerFax helps patients navigate blood cancer treatment options and access internationally
Understanding Blood Cancers: Leukemia, Lymphoma, and Myeloma
Blood cancers are not a single disease — they are over 80 distinct malignancies, each with different biology, treatment algorithms, and outcomes. Correct subtyping by a specialist haematopathologist is non-negotiable before any treatment decision.
“A diagnosis made without immunophenotyping, cytogenetics, FISH, and NGS is incomplete — and an incomplete diagnosis leads to incomplete treatment.”
Leukemia: Blood and Bone Marrow
Abnormal blast cell proliferation in bone marrow crowds out normal haematopoiesis. Acute (AML, ALL) = medical emergency requiring immediate treatment. Chronic (CML, CLL) = slower progression, often manageable with targeted agents. Subtype determines everything: APL (>90% cure), adverse-risk AML (requires transplant), Ph+ ALL (TKI essential).
Lymphoma: Lymphatic System
B-cell, T-cell, or NK-cell origin. Hodgkin lymphoma (80–85% cure even advanced). Non-Hodgkin lymphoma (60+ subtypes): indolent (follicular — decades survival, watch-and-wait appropriate) to aggressive (DLBCL — R-CHOP curative in 60–70%; CAR-T for relapsed). ENKTL is Asia-specific: 5–10% of NHL in China vs <1% in the West.
Multiple Myeloma: Plasma Cells
Malignant plasma cells infiltrate bone marrow, produce paraprotein, cause end-organ damage (CRAB: hypercalcaemia, renal failure, anaemia, bone lesions). Not curable in most patients but median survival improved from 2–3 years to 6–10+ years with triplet induction, ASCT, and maintenance. BCMA-targeted CAR-T achieves 73% CR in penta-refractory disease (CARTITUDE-1).
Why Subspecialist Expertise is Non-Negotiable
DLBCL treatment is entirely different from follicular lymphoma despite both being B-cell lymphoma. AML treatment varies dramatically by cytogenetic risk. Myeloma management depends on transplant eligibility, cytogenetic risk, and renal function. China's and India's top centres have separate leukemia, lymphoma, and myeloma teams with dedicated tumour boards.
Molecular Profiling: The Mandatory Test Panel Before Any Treatment
Comprehensive molecular profiling determines treatment eligibility, risk stratification, targeted therapy selection, and MRD monitoring strategy. Every test listed below is required — not optional — before first-line treatment begins.
| Test | What It Detects | Clinical Use | Required For |
|---|---|---|---|
| Flow cytometry (immunophenotyping) | Cell surface markers (CD antigens); lineage assignment | B-cell vs T-cell vs myeloid classification; MRD monitoring | All leukemia and lymphoma — mandatory at diagnosis |
| Conventional karyotype (cytogenetics) | Chromosomal gains, losses, translocations (e.g. t(15;17), t(9;22), t(8;21)) | Primary risk stratification; treatment selection (e.g. APL vs AML, Ph+ ALL) | AML, ALL, CML, MDS, myeloma — mandatory |
| FISH panel | Specific translocations/deletions with high sensitivity (BCR-ABL, MLL, del17p, t(4;14)) | Confirms or refines karyotype; detects targets missed by standard cytogenetics | ALL (BCR-ABL, KMT2A), myeloma (del17p, t(4;14), t(14;16), gain1q21) |
| NGS gene panel (30–80 genes) | Point mutations and small insertions/deletions (FLT3, NPM1, IDH1/2, TP53, RUNX1) | Targeted therapy eligibility (FLT3i, IDHi, venetoclax); prognosis; MRD | AML, CLL (IGHV, TP53), myeloma — mandatory before treatment |
| BCR-ABL PCR (quantitative) | Philadelphia chromosome transcript level (IS scale) | CML diagnosis; TKI response monitoring (MMR, MR4, MR4.5); TFR eligibility | CML; Ph+ ALL — mandatory at diagnosis and every 3 months on TKI |
| Minimal residual disease (MRD) | Residual cancer cells below standard detection (1 in 10,000–100,000) | Strongest predictor of long-term remission; guides transplant timing; de-escalation in myeloma | ALL post-induction (transplant decision); myeloma; AML consolidation |
Leukemia Treatment: Acute and Chronic — Key Breakthroughs
Acute leukemias are medical emergencies requiring rapid, risk-adapted treatment. Chronic leukemias have been transformed by TKI and BTK inhibitor therapy — many patients now achieve chemotherapy-free, near-normal life expectancy.
AML: 7+3 Induction + Risk-Adapted Consolidation + Targeted Agents
Standard 7+3 (cytarabine + anthracycline) achieves CR in 60–80% of younger patients. Risk stratification determines consolidation: favourable-risk (NPM1+, CBF-AML) → HiDAC cycles; adverse-risk → allogeneic SCT in CR1. Targeted additions: midostaurin with 7+3 (FLT3-ITD); venetoclax + azacitidine for unfit patients (VIALE-A: 36–37% CR). IDH1/2 inhibitors (ivosidenib, enasidenib) for relapsed/refractory IDH-mutated AML.
APL: The Most Curable Leukemia — ATRA/ATO Regimen (Ruijin Hospital Pioneer)
APL (t(15;17), PML-RARA) achieves >90% cure with ATRA + arsenic trioxide (ATO) — no conventional chemotherapy required for standard-risk APL. This regimen was pioneered at Ruijin Hospital Shanghai and is now the global standard. APL is a medical emergency: ATRA must be started immediately on clinical suspicion before molecular confirmation due to life-threatening coagulopathy. Ruijin Hospital remains the world reference centre for APL.
ALL: Intensive Regimens, TKIs for Ph+ ALL, and Blinatumomab
Paediatric-inspired intensive regimens achieve >90% CR in adults; 40–50% long-term cure in adult ALL vs >80% paediatric. Ph+ ALL (BCR-ABL+): addition of TKIs (dasatinib, ponatinib) with reduced-intensity chemo → >90% CR, dramatically improved survival. Blinatumomab (CD19/CD3 BiTE) approved for relapsed/refractory B-ALL; increasingly used in MRD+ consolidation to clear residual disease and avoid transplant.
CML: TKI Success Story — Normal Life Expectancy Achievable
CML was fatal within 3–5 years before imatinib (2001). Now the majority of patients on TKI therapy have normal life expectancy. 2nd-gen TKIs (dasatinib, nilotinib, bosutinib) achieve faster/deeper molecular responses. Ponatinib for T315I mutation. Treatment-free remission (TFR) possible for patients achieving sustained MR4/MR4.5. Generic imatinib: USD 50–150/month in India vs USD 2,000–4,000 in USA.
CLL Targeted Agents: BTK Inhibitors and BCL-2 Inhibitors
Chemotherapy-free treatment is now standard for CLL. Zanubrutinib (BeiGene, China-developed) has demonstrated superiority over ibrutinib in the ALPINE trial — best-in-class BTK inhibitor available in China at competitive cost.
| Drug Class | Key Drug(s) | CLL Indication | China Availability | India Availability |
|---|---|---|---|---|
| BTK inhibitor (1st gen) | Ibrutinib | All lines; first and subsequent | Yes — NMPA approved + generics available | Yes — generic available at major centres |
| BTK inhibitor (2nd gen) | Zanubrutinib (Brukinsa — China-developed by BeiGene) | All lines; fewer cardiovascular AEs; ALPINE: superior to ibrutinib in CLL | Yes — NMPA approved; cost-preferred over imported BTKi | Yes — available at major centres |
| BTK inhibitor (2nd gen) | Acalabrutinib | All lines; favourable safety profile | Available at specialist centres | Available at major centres |
| BCL-2 inhibitor | Venetoclax | Fixed-duration combination (12 months); del17p/TP53; deep MRD-negative remission | Yes — NMPA approved | Yes — available at major centres |
| Anti-CD20 antibody | Rituximab / Obinutuzumab | Combination with venetoclax or chemoimmunotherapy | Both NMPA approved | Both available |
| PI3K inhibitor | Idelalisib / Copanlisib | Relapsed/refractory; salvage | Available at specialist centres | Available at major centres |
Lymphoma Treatment: Hodgkin, DLBCL, Follicular, and T-Cell
Lymphoma treatment is subtype-specific. Hodgkin lymphoma is among the most curable cancers. DLBCL is cured by R-CHOP in 60–70% — but relapsed/refractory disease has been transformed by CAR-T. ENKTL is Asia's distinctive challenge and China leads globally in its management.
Hodgkin Lymphoma: 80–85% Cure Rate
ABVD standard first-line (40+ years). PET-adapted approach: interim PET-negative patients avoid bleomycin (RATHL trial); PET-positive receive escalation. BV-AVD (brentuximab vedotin + AVD) now preferred for advanced disease at specialist centres. Pembrolizumab: 65–87% ORR in relapsed/refractory HL — one of highest immunotherapy response rates in any malignancy.
DLBCL: R-CHOP → CAR-T at Relapse
R-CHOP cures 60–70%. Pola-R-CHP (polatuzumab vedotin + R-CHP) superior PFS vs R-CHOP (POLARIX trial) — adopted at Chinese/Indian centres for high-risk patients. 30–40% relapse: CAR-T (axi-cel, tisa-cel, liso-cel) achieves 40–54% CR in relapsed/refractory DLBCL. ZUMA-7 and TRANSFORM: CAR-T superior to salvage chemo + ASCT as second-line.
Follicular Lymphoma: Watch-and-Wait First
Asymptomatic, low-volume follicular lymphoma: no treatment needed (multiple RCTs show immediate chemo does not improve survival). Median time to first treatment: 2–3 years. When treatment required: R-bendamustine (preferred over R-CHOP, BRIGHT/StiL trials). Relapsed: CAR-T achieves 60–70% CR — higher than DLBCL. EZH2 inhibitor tazemetostat active in EZH2-mutated disease (~20%).
ENKTL (NK/T-Cell): Asia's Disease — China Leads Globally
EBV-associated; 5–10% of NHL in China/Korea/Japan vs <1% in Western Europe. CHOP is ineffective (P-glycoprotein resistance). L-asparaginase-based regimens (SMILE, DDGP, P-Gemox) are essential. Chinese hematology centres have the world's largest ENKTL case series and deepest clinical expertise. Critical for patients from Vietnam, Thailand, Malaysia, Indonesia — route to Chinese centres.
Multiple Myeloma: Treatment by Setting
Myeloma treatment has evolved from median survival of 2–3 years to 6–10+ years. Daratumumab (anti-CD38) is now the backbone of all frontline regimens. BCMA-targeted CAR-T (cilta-cel) achieves 73% CR in penta-refractory disease — available in China at USD 40,000–75,000.
| Setting | Preferred Regimen | Key Trial | China | India |
|---|---|---|---|---|
| Transplant-eligible NDMM | Dara-VRd × 4 cycles → ASCT → Dara maintenance | GRIFFIN | Yes — NMPA approved | At major centres |
| Transplant-ineligible NDMM | Dara-VRd or Dara-Rd (DRd) | MAIA | Yes | At major centres |
| Renal impairment at diagnosis | VCd (bortezomib + cyclophosphamide + dex) | Multiple | Yes | Yes |
| Relapsed 1–3 prior lines | Dara-Kd, Dara-Pd, Elo-Pd, Isa-Kd | CANDOR, APOLLO, ELOQUENT | Yes — NMPA approved | At major centres |
| Penta-refractory myeloma | BCMA CAR-T (cilta-cel: 73% CR; ide-cel: 28–33% CR) or bispecific (teclistamab: 63% ORR) | CARTITUDE-1, KarMMa, MajesTEC-1 | BCMA CAR-T NMPA approved — USD 40,000–75,000 | Limited; clinical trials only |
NMPA-Approved CAR-T Products in China
China is the only country where CAR-T therapy is both clinically proven and economically accessible for international patients. All five products below are NMPA-approved and available at licensed specialist centres at 10–15% of US prices.
| CAR-T Product | Target | Approved Indication | Manufacturer | Cost in China (USD) |
|---|---|---|---|---|
| Axicabtagene ciloleucel (Yescarta) | CD19 | Relapsed/refractory DLBCL, follicular lymphoma (2L+) | Fosun Kite (China) | 35,000–55,000 |
| Relma-cel / CT103A (Carteyva) | CD19 | Relapsed/refractory DLBCL | JW Therapeutics (China) | 35,000–50,000 |
| Relmacabtagene autoleucel | CD19 | Relapsed/refractory ALL | JW Therapeutics (China) | 35,000–55,000 |
| Equecabtagene autoleucel (Fucaso) | BCMA | Relapsed/refractory myeloma (4L+) | Nanjing IASO Bio (China) | 40,000–65,000 |
| Ciltacabtagene autoleucel (Carvykti) | BCMA | Relapsed/refractory myeloma — 73% CR (CARTITUDE-1) | Janssen / Legend Biotech (China partnership) | 50,000–75,000 |
CancerFax CAR-T Access Pathway for China (6–10 Week Timeline)
CAR-T therapy requires careful coordination across eligibility assessment, leukapheresis, manufacturing, bridging therapy, infusion, and post-CAR-T monitoring. CancerFax manages the entire process for international patients.
- 1
Eligibility Assessment (Week 1–2)
CancerFax reviews full medical history against CAR-T eligibility criteria: prior line requirements, performance status (ECOG 0–1), organ function thresholds (renal, hepatic, cardiac), absence of active CNS disease, and adequate disease burden for response assessment. Contact immediately for rapidly progressing disease — earlier referral enables bridging therapy planning.
- 2
Centre Selection and Leukapheresis (Week 2–3)
CAR-T products are licensed at specific centres. CancerFax matches product selection to disease profile: CD19 for DLBCL/ALL/FL → Peking University People's Hospital, Zhejiang University First Affiliated, Tongji Hospital Wuhan; BCMA for myeloma → IASO Bio-partnered centres. Leukapheresis (T-cell collection) is timed as the first inpatient step upon arrival in China.
- 3
Manufacturing and Bridging Therapy (Week 3–7)
CAR-T manufacturing takes 3–5 weeks from leukapheresis. During this period, patients either remain in China or return home with a bridging chemotherapy plan coordinated between the Chinese team and local oncologist. CancerFax facilitates communication between both teams throughout manufacturing.
- 4
Lymphodepletion and CAR-T Infusion (Week 7–8)
Lymphodepleting chemotherapy (fludarabine + cyclophosphamide) 5 days before infusion. CAR-T infusion on Day 0. All performed at the licensed treatment centre with specialist hematology units capable of managing cytokine release syndrome (CRS) and ICANS (immune effector cell-associated neurotoxicity syndrome).
- 5
CRS/ICANS Monitoring (Week 8–12)
2–4 week inpatient monitoring period post-infusion. CRS (fever, hypotension, hypoxia) managed with tocilizumab and corticosteroids. ICANS (neurological toxicity) monitored with ICANS grading. CancerFax coordinates accommodation for accompanying family members during this period.
- 6
Post-CAR-T Follow-Up (Day 30 / Day 90 / 6 Months)
Response assessment at Day 30 (PET-CT for lymphoma; bone marrow biopsy + MRD for myeloma/ALL), Day 90, and 6 months. Late toxicity monitoring: B-cell aplasia, hypogammaglobulinemia (requires IgG replacement), prolonged cytopenias. CancerFax coordinates telemedicine follow-up with the Chinese treating team and local oncologist for ongoing case management.
Stem Cell Transplant Costs: China vs India vs USA
China and India together perform more than 15,000 haematopoietic stem cell transplants annually. Both countries offer transplant costs at 85–90% lower than USA equivalents. The Beijing Protocol haploidentical approach eliminates the donor availability barrier — a parent, sibling, or child is available for virtually every patient.
Autologous SCT (Myeloma / Lymphoma)
- IndiaUSD 12,000–22,000
- ChinaUSD 18,000–30,000
- USAUSD 150,000–250,000
Allogeneic SCT — Haploidentical (Beijing Protocol)
- IndiaUSD 22,000–42,000
- ChinaUSD 30,000–55,000
- USAUSD 300,000–500,000
CAR-T Therapy (CD19 — DLBCL/ALL)
- China (NMPA-approved)USD 35,000–55,000
- USA (FDA-approved)USD 350,000–450,000
China vs India: Which Country for Which Blood Cancer Patient?
CancerFax routes patients based on clinical need. China and India each have distinct and complementary strengths across the blood cancer treatment spectrum.
China For
- CAR-T therapy — the only globally accessible optionNMPA-approved CD19 and BCMA CAR-T at USD 35,000–75,000. Only option for international patients who cannot afford USD 350,000–460,000 in the USA.
- Haploidentical transplant — Beijing Protocol world referencePeking University People's Hospital: highest global volume of haplo-SCT. Every patient has a haploidentical donor (parent, sibling, child) — eliminates donor availability barrier.
- APL management — Ruijin Hospital: global reference centreATRA/ATO regimen for APL was pioneered here. Unmatched experience; essential for patients who need ATRA and ATO monitoring expertise.
- ENKTL and Asian-specific lymphomasWorld's largest ENKTL case series and L-asparaginase regimen expertise. Essential for patients from Vietnam, Thailand, Malaysia, Indonesia, Korea.
- China-developed novel drugs at lower costZanubrutinib (BeiGene) for CLL/MCL; sintilimab; domestic venetoclax generics. Cost-competitive against imported branded equivalents.
India For
- Cost-accessible allogeneic and autologous transplantAllogeneic SCT from USD 20,000–40,000 at CMC Vellore, Tata Memorial, Apollo — substantially lower than China and fraction of Western costs.
- Geographic and cultural accessibility from South AsiaBangladesh, Nepal, Sri Lanka, Pakistan, East Africa, Gulf — closer, lower travel cost, English-language clinical environment, culturally familiar.
- ALL management — CMC Vellore: Asia's largest ALL programmePaediatric-inspired ALL regimens in adults with published international outcomes; MRD-guided therapy; allogeneic transplant for high-risk ALL.
- Living donor haematopoietic transplant traditionStrong LDLT and haploidentical SCT culture maximises donor availability; experienced teams across Tata Memorial, CMC Vellore, Narayana, Apollo.
- Generic TKI access at lowest global costGeneric imatinib: USD 50–150/month in India vs USD 2,000–4,000 in USA. BTK inhibitor generics available for CML and CLL at fraction of branded pricing.
Blood Cancer Treatment Costs: China vs India vs USA
Treatment costs in China and India are 80–95% lower than in the USA across all categories. China's domestic drug pipeline (zanubrutinib, sintilimab, venetoclax generics) provides additional cost advantages not available elsewhere.
| Treatment | China (USD) | India (USD) | USA (USD) |
|---|---|---|---|
| CAR-T therapy — CD19 (DLBCL/ALL) | 35,000–55,000 | Not yet widely available | 350,000–450,000 |
| CAR-T therapy — BCMA (myeloma) | 40,000–70,000 | Limited; clinical trials | 400,000–460,000 |
| Allogeneic SCT (haploidentical) | 30,000–55,000 | 22,000–42,000 | 300,000–500,000 |
| Autologous SCT (myeloma/lymphoma) | 18,000–30,000 | 12,000–22,000 | 150,000–250,000 |
| AML induction + consolidation (4–6 months) | 15,000–30,000 | 10,000–20,000 | 150,000–300,000 |
| Venetoclax + azacitidine (per cycle) | 2,000–4,000 | 1,500–3,500 | 25,000–35,000 |
| Daratumumab (per infusion) | 800–1,800 | 600–1,500 | 8,000–12,000 |
| Zanubrutinib / ibrutinib (per month) | 500–1,200 (generic/domestic) | 300–900 (generic) | 12,000–16,000 (branded) |
| Blinatumomab (per cycle) | 8,000–15,000 | 6,000–12,000 | 80,000–120,000 |
| Comprehensive NGS + cytogenetics panel | 800–1,800 | 500–1,500 | 3,000–8,000 |
Frequently Asked Questions
Diagnosis and Molecular Profiling
What diagnostic tests are mandatory before starting any blood cancer treatment?
Before any blood cancer treatment begins, the following are mandatory: bone marrow biopsy with aspirate (both trephine and liquid), immunophenotyping by flow cytometry (for lineage assignment and MRD baseline), conventional karyotype (chromosomal analysis), FISH panel for disease-relevant targets (BCR-ABL, del17p, t(4;14) for myeloma; MLL/KMT2A for ALL; specific targets for each disease), and NGS gene panel (FLT3, NPM1, IDH1, IDH2, TP53, RUNX1 for AML; IGHV mutation, TP53, del17p for CLL; del17p, t(4;14), t(14;16), gain1q21 for myeloma). Starting treatment without this complete panel means treating based on an incomplete diagnosis, which leads to incorrect risk stratification, missed targeted therapy eligibility, and incorrect treatment intensity. CancerFax reviews each patient's existing workup and identifies missing tests that must be completed before a treatment recommendation can be made.
What is MRD testing and why does it matter for blood cancer treatment decisions?
Minimal residual disease (MRD) testing detects residual cancer cells below the threshold of standard microscopy — finding as few as 1 cancer cell in 10,000 or 100,000 normal cells using highly sensitive flow cytometry or molecular PCR/NGS methods. MRD status after induction or consolidation therapy is now the strongest predictor of long-term remission in ALL, myeloma, and increasingly AML. Practically, MRD status drives critical treatment decisions: MRD-positive ALL after induction indicates higher relapse risk and prompts referral for allogeneic stem cell transplant; MRD-negative myeloma after induction and transplant allows consideration of de-escalating maintenance therapy; MRD-positive AML after consolidation indicates high relapse risk and prompts salvage therapy rather than observation. MRD assessment is standard practice at Chinese and Indian specialist haematology centres and should be confirmed as part of any treatment plan.
CAR-T Therapy Access
Why is China the only realistic option for affordable CAR-T therapy for international patients?
CAR-T cell therapy in the United States costs USD 350,000–450,000 for CD19-targeted products (axi-cel, tisa-cel, liso-cel) and USD 400,000–460,000 for BCMA-targeted products (cilta-cel, ide-cel) — before hospital fees, supportive care costs, and management of complications. In the United Kingdom, Europe, and Australia, the approved products are similarly priced or restricted. In China, NMPA-approved CAR-T products manufactured domestically by Fosun Kite and JW Therapeutics (CD19) and Nanjing IASO Bio (BCMA) are available at USD 35,000–75,000 — the same technology at approximately 10–15% of Western cost. No other country in the world offers commercially approved CAR-T therapy at this price point. For patients from South Asia, Southeast Asia, the Middle East, and Africa who need CAR-T for relapsed DLBCL, ALL, follicular lymphoma, or myeloma, China is the only economically viable option.
How long does the CAR-T process take and what is involved for international patients?
The typical timeline from first contact to CAR-T infusion in China is 6–10 weeks. This includes 1–2 weeks for eligibility review and admission planning, travel to China and leukapheresis (T-cell collection, approximately 1 week), 3–5 weeks for CAR-T manufacturing, 1 week for lymphodepleting chemotherapy, the infusion day, and 2–4 weeks of inpatient monitoring for cytokine release syndrome (CRS) and ICANS. During the manufacturing period, patients may return home with a bridging chemotherapy plan coordinated between the Chinese treating team and the local oncologist. CancerFax manages the entire process — eligibility assessment, centre selection, leukapheresis scheduling, bridging therapy coordination, infusion hospitalisation, and post-CAR-T monitoring — as a structured service for international patients. Patients with rapidly progressing disease should contact CancerFax immediately; earlier referral enables bridging therapy planning and avoids disease progression that could render the patient ineligible.
Stem Cell Transplant and Novel Agents
I have no matched sibling donor. Does that mean I cannot have an allogeneic transplant?
No — the Beijing Protocol haploidentical transplant developed at Peking University People's Hospital by Professor Huang Xiaojun has effectively solved the donor availability problem. Haploidentical donors — parents, siblings, children — are half-matched (50% HLA match) rather than fully matched. The Beijing Protocol uses a specific combination of G-CSF-mobilised bone marrow and peripheral blood stem cells with tailored GvHD prophylaxis, and has demonstrated safety and efficacy comparable to matched sibling transplant. Because virtually every patient has a haploidentical family member available, this approach has enabled allogeneic transplantation for patients who would otherwise have no curative option. China performs more haploidentical transplants than any other country globally, and the Beijing Protocol has been adopted internationally as the benchmark haploidentical approach. For patients without a matched sibling or matched unrelated donor, referral to Peking University People's Hospital or other high-volume Chinese haploidentical centres should be the first step.
What is zanubrutinib and why might it be a better BTK inhibitor than ibrutinib for CLL?
Zanubrutinib (brand name Brukinsa) is a second-generation BTK inhibitor developed by BeiGene, a Beijing-founded biopharmaceutical company. It was designed to achieve more complete and selective BTK inhibition than ibrutinib, with reduced off-target kinase activity that is responsible for ibrutinib's cardiovascular side effects (atrial fibrillation, hypertension, bleeding). The ALPINE randomised trial compared zanubrutinib directly with ibrutinib in CLL patients and demonstrated superior overall response rate (zanubrutinib 78.3% vs ibrutinib 62.5%) with significantly fewer cardiovascular adverse events. This makes zanubrutinib the current best-in-class BTK inhibitor for CLL based on head-to-head evidence. As a domestically developed drug, zanubrutinib is available in China at substantially lower cost than imported ibrutinib or acalabrutinib, making it the preferred BTK inhibitor choice for CLL patients treated at Chinese haematology centres.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Ready to Access Blood Cancer Treatment in China or India?
Upload your bone marrow biopsy report, cytogenetics, NGS results, and treatment history. CancerFax will assess whether your diagnostic workup is complete, identify CAR-T eligibility or transplant options, and connect you with the right specialist — with second opinions available within 5–7 business days.
This content is for informational purposes only and does not constitute medical advice. Blood cancer treatment is highly individualised and depends on disease subtype, molecular profile, cytogenetic risk, and prior treatment history. All decisions must be made in consultation with a qualified haematological oncology specialist.